Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00323570
Status:
WITHDRAWN
Last Update Posted:
2012-06-27
First Post:
2006-05-08
Brief Title:
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A Multi-center Randomized Double-blind Parallel Group Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII rFVIIaNovoSeven NiaStase in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients
Status:
WITHDRAWN
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in the United States of America USA The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma
Please note that this trial and trial F7TRAUMA-1711 NCT00184548 have been merged
Please note that this trial and trial F7TRAUMA-1711 NCT00184548 have been merged
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None